An accelerated pathway for targeted cancer therapies

Related Experiment Video

Updated: Jun 4, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Mark McClellan1, Joshua Benner, Richard Schilsky

  • 1Engelberg Center for Health Care Reform, Brookings Institution, Washington DC, USA.

Nature Reviews. Drug Discovery
|February 2, 2011
PubMed

Insights

A clear pathway for developing and approving targeted cancer therapies and companion diagnostics can speed up the process, reduce risks for developers, and encourage innovation in cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Biotechnology

Background:

  • Targeted cancer therapies offer personalized treatment strategies.
  • Companion diagnostics are crucial for identifying patients who will benefit from specific targeted therapies.
  • Current development pathways can be lengthy and uncertain, impacting drug and diagnostic innovation.

Purpose of the Study:

  • To outline the need for a streamlined regulatory pathway for targeted cancer therapies and companion diagnostics.
  • To highlight how a defined pathway can reduce development uncertainty and improve efficiency.
  • To emphasize the potential of such a pathway to incentivize developers.

Main Methods:

  • Analysis of existing regulatory frameworks for drug and diagnostic development.
  • Review of challenges and bottlenecks in the current accelerated approval processes.
  • Formulation of recommendations for an integrated pathway.

Main Results:

  • A well-defined pathway can significantly reduce the time and cost associated with bringing targeted therapies and companion diagnostics to market.
  • Improved regulatory clarity fosters greater investment and reduces developer risk.
  • Accelerated development leads to faster patient access to life-saving treatments.

Conclusions:

  • Establishing a clear, integrated pathway for targeted cancer therapies and companion diagnostics is essential for advancing precision oncology.
  • This streamlined approach will enhance efficiency, reduce uncertainty, and provide a strong incentive for pharmaceutical and biotech developers.
  • Ultimately, this benefits patients by ensuring timely access to innovative cancer treatments.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.